SavePeptides
SavePeptidesCompound
Re-checked hourly
All peptides
Weight LossPhase IIIVendors pending
Phase IIIVendors pendingFacts verified · 2026-05-25

Cagrilintide

Also known as am833, nn0174-0833, long-acting amylin analogue · Wikipedia

Cagrilintide (NN0174-0833, AM833) is a long-acting acylated amylin analog developed by Novo Nordisk for chronic weight management. Built on the pramlintide backbone with stabilizing substitutions and an N-terminal fatty-acid side chain enabling once-weekly subcutaneous dosing, it activates amylin and calcitonin receptors in the area postrema and hypothalamus to amplify satiety and slow gastric emptying. It is primarily developed as the CagriSema fixed-ratio combination with semaglutide 2.4 mg, evaluated across the REDEFINE phase 3 program in obesity and type 2 diabetes. It is not yet approved by FDA or EMA. Also known as AM833 and NN0174-0833.

—

best

price

—

per

mg

—

vendors

tracked

Phase III

stage

Vendor data

Coming soon.

Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.

Browse all vendors

Mechanism of action

Cagrilintide is a long-acting amylin analog derived from the pramlintide sequence with N14E/V17R/P37Y substitutions and N-terminal lysine lipidation (C20 diacid via gamma-Glu), giving an approximately 7-8 day subcutaneous half-life via albumin binding. It is a non-selective agonist at amylin receptors (AMY1, AMY2, AMY3 - heterodimers of the calcitonin receptor with RAMP1/2/3) and at the calcitonin receptor itself.

Cagrilintide is a long-acting amylin analog derived from the pramlintide sequence with N14E/V17R/P37Y substitutions and N-terminal lysine lipidation (C20 diacid via gamma-Glu), giving an approximately 7-8 day subcutaneous half-life via albumin binding. It is a non-selective agonist at amylin receptors (AMY1, AMY2, AMY3 - heterodimers of the calcitonin receptor with RAMP1/2/3) and at the calcitonin receptor itself. In rodent and primate work it reduces bodyweight predominantly through central amylin receptors AMY1 and AMY3 in the area postrema and hindbrain (https://pmc.ncbi.nlm.nih.gov/articles/PMC12270663/), producing satiety, slowed gastric emptying, and reduced postprandial glucagon. The mechanism is non-incretin and complements GLP-1 receptor agonism, supporting additive weight loss in the CagriSema combination (https://pubmed.ncbi.nlm.nih.gov/34288673/).

Pharmacokinetic properties

Half-life

~7-8 days subcutaneous

Routes

subcutaneous

Bioavailability

Fatty-acid acylation provides albumin binding for once-weekly dosing; not orally bioavailable.

Amino-acid sequence

Pramlintide backbone (37 aa) with substitutions N14E, V17R, P37Y; N-terminal Lys lipidated (C20 diacid-gammaGlu)

Use & research dosing

Fat LossAppetite ControlSatiety SupportWeight LossEnergy

Phase 1-3 trial doses ranged from 0.16 to 4.5 mg subcutaneous weekly, titrated up over 4-16 weeks to manage GI tolerability. In the REDEFINE-1 phase 3a trial, the CagriSema combination was dosed as cagrilintide 2.4 mg plus semaglutide 2.4 mg once weekly. Not FDA- or EMA-approved in any form; no validated monotherapy dose for general use exists. Research framing only.

Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.

Editorial perspective

REDEFINE-1 (phase 3a, 68 weeks, ~3,400 adults without diabetes) reported mean weight change of approximately -20.4% with CagriSema vs -3.0% with placebo, slightly below pre-trial expectations of ~25% but still the strongest data to date for an amylin/GLP-1 combination. REDEFINE-2 covers overweight/obesity with type 2 diabetes. Cagrilintide is most often discussed as part of CagriSema rather than as a standalone agent.

— SavePeptides editorial desk · last updated 2026-05-25

Cautions & contraindications

Before researching this compound, note:

  • Not FDA- or EMA-approved; investigational
  • Personal or family history of pancreatitis (theoretical class concern)
  • Pregnancy and breastfeeding - avoid
  • Severe gastroparesis or pre-existing significant GI motility disorder
  • GI side effects (nausea, vomiting, constipation) are common, especially during titration
  • Injection site reactions
  • Hypoglycemia risk when combined with insulin or sulfonylureas in diabetes
  • Personal or family history of medullary thyroid carcinoma or MEN2 (class caution from amylin/incretin program)

Research foundation

The papers behind the page.

  1. [01]https://www.nejm.org/doi/full/10.1056/NEJMoa2502081
  2. [02]https://www.nejm.org/doi/full/10.1056/NEJMoa2502082
  3. [03]https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00845-X/abstract
  4. [04]https://pmc.ncbi.nlm.nih.gov/articles/PMC12270663/
  5. [05]https://pubmed.ncbi.nlm.nih.gov/34288673/

Facts verified

2026-05-25

Confidence

high

What this means

  • No editorial caveats on this entry — claims map to peer-reviewed sources cited above.

How we check →

Vendor data coming soon

All vendors

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.